Table 1 Characteristics and association between SIRPB1 expression and clinicopathologic features of patients with glioma based on TCGA
Variable | No | SIRPB1 expression | P | |
|---|---|---|---|---|
Low (%) | High (%) | |||
WHO grade | ||||
 WHO-II | 216 | 138 (46.9%) | 78 (24.5%) |  < 0.001 |
 WHO-III | 237 | 127 (43.2%) | 110 (34.5%) | |
 WHO-IV | 160 | 29 (9.9%) | 131 (41.1%) | |
IDH status | ||||
 Mutant | 424 | 266 (80.4%) | 158 (47.9%) |  < 0.001 |
 Wild type | 237 | 65 (19.6%) | 172 (52.1%) | |
1p/19q co-deletion | ||||
 Co-deletion | 168 | 123 (36.8%) | 45 (13.6%) |  < 0.001 |
 Non-co-deletion | 496 | 211 (63.2%) | 285 (86.4%) | |
Primary therapy outcome | ||||
 CR | 135 | 93 (35.1%) | 42 (23.5%) | 0.016 |
 PD | 103 | 50 (18.9%) | 53 (29.6%) | |
 PR | 62 | 35 (13.2%) | 27 (15.1%) | |
 SD | 144 | 87 (32.8%) | 57 (31.8%) | |
Gender | ||||
 Female | 284 | 154 (46.0%) | 130 (38.8%) | 0.072 |
 Male | 386 | 181 (54.0%) | 205 (61.2%) | |
Race | ||||
 Asian | 13 | 6 (1.8%) | 7 (2.1%) | 0.897 |
 Black or African American | 32 | 15 (4.6%) | 17 (5.2%) | |
 White | 613 | 308 (93.6%) | 305 (92.7%) | |
Histological type | ||||
 Astrocytoma | 192 | 103 (30.7%) | 89 (26.6%) |  < 0.001 |
 Glioblastoma | 160 | 29 (8.7%) | 131 (39.1%) | |
 Oligoastrocytoma | 128 | 75 (22.4%) | 53 (15.8%) | |
 Oligodendroglioma | 190 | 128 (38.2%) | 62 (18.5%) | |
EGFR status | ||||
 Mutant | 73 | 28 (8.6%) | 45 (13.7%) | 0.05 |
 Wild type | 583 | 299 (91.4%) | 284 (86.3%) | |
PIK3CA status | ||||
 Mutant | 49 | 24 (7.3%) | 25 (7.6%) | 1 |
 Wild type | 607 | 303 (92.7%) | 304 (92.4%) | |
Age# | 42.00 [33.00,55.00] | 50.00 [36.00,61.00] |  < 0.001 | |